Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Sell
5
MLTX Quote, Financials, Valuation and Earnings
Last price:
$49.24
Seasonality move
:
19.72%
Day range:
$50.00 - $52.80
52-week range:
$37.55 - $64.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.49x
Volume:
538K
Avg. volume:
220.8K
1-year change:
-8.17%
Market cap:
$3.2B
Revenue:
--
EPS (TTM):
-$1.27
Earnings Data
Next earnings date for MLTX
Feb 28
2025
Most recent earnings per share
-$0.56
Missed by $0.11
(Nov 7/2024)
Consensus Estimate
-$0.45
(Nov 7/2024)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
MLTX Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 03/31/2025 | Q1 | -- | -- | -- | -$0.62 | -- |
| 02/28/2025 | Q4 | -- | -- | -- | -$0.62 | -- |
| 11/07/2024 | Q3 | -- | -- | -$0.56 | -$0.45 | -$0.11 |
| 08/07/2024 | Q2 | -- | -- | -$0.39 | -$0.28 | -$0.11 |
| 05/07/2024 | Q1 | -- | -- | -$0.22 | -$0.21 | -$0.01 |
| 02/29/2024 | Q4 | -- | -- | -$0.10 | -$0.27 | $0.17 |
| 11/14/2023 | Q3 | -- | -- | -$0.18 | -$0.25 | $0.07 |
| 08/10/2023 | Q2 | -- | -- | -$0.23 | -$0.29 | $0.06 |
| 05/11/2023 | Q1 | -- | -- | -$0.23 | -$0.29 | $0.06 |
| 03/20/2023 | Q4 | -- | -- | -$0.31 | -$0.28 | -$0.03 |
| 11/14/2022 | Q3 | -- | -- | -$0.27 | -- | -- |
| 08/12/2022 | Q2 | -- | -- | -$0.34 | -- | -- |
| 03/31/2022 | Q1 | -- | -- | -$0.43 | -- | -- |
| 09/30/2021 | Q3 | -- | -- | -$0.17 | -- | -- |
| 06/30/2021 | Q2 | -- | -- | -$0.89 | -- | -- |
MoonLake Immunotherapeutics Earnings Questions
-
How Much did MoonLake Immunotherapeutics Generate in Revenue Last Quarter?
MoonLake Immunotherapeutics reported -- worth of top line sales in its most recent quarter.
-
Did MoonLake Immunotherapeutics Beat Earnings Last Quarter?
MoonLake Immunotherapeutics announced earnings per share of -$0.56 which represents a miss of analyst forecast a -$0.45 per share.
-
Is MoonLake Immunotherapeutics Profitable?
MoonLake Immunotherapeutics reported -- that represents -- per share over the last quarter.
-
What is the Analyst Consensus for MoonLake Immunotherapeutics EPS Next Year?
MoonLake Immunotherapeutics's earnings are forecast to decrease from -$0.73 per share to -$1.77 per share next year representing a decrease of -149.36%.
-
When is MoonLake Immunotherapeutics's Earnings Date?
MoonLake Immunotherapeutics's next earnings date is February 28, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
3 High Dividend Dow Jones Stocks
Thanks to surging stock prices over the past two years,…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is down 0.11% over the past day.
Buy
69
UNF alert for Jan 8
UniFirst [UNF] is up 3.15% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 8.72% over the past day.
